Shengmai Formula Ameliorates Pathological Characteristics in AD C. elegans

Cellular and Molecular Neurobiology

Volumn 36, Issue 8, 2016, Pages 1291-1302

  Zhang, Weimin ^a   Zhi, Dejuan ^a   Ren, Hui ^a   Wang, Dong ^a   Wang, Xin ^a   Zhang, Zhanxin ^a   Fei, Dongqing ^a   Zhu, Hongmei ^a   Li, Hongyu ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

AD; Caenorhabditis elegans; Chemotaxis; Paralysis; SM formula; Synergistic effect

Indexed keywords

ALCOHOL; AMYLOID BETA PROTEIN; CHINESE DRUG; FLAVONE DERIVATIVE; LIGNIN; NOOTROPIC AGENT; SAPONIN DERIVATIVE; SHENGMAI FORMULA; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); HERBACEOUS AGENT; OPHIOPOGON ROOT; PEPTIDE FRAGMENT; SHENGMAI;

ALZHEIMER DISEASE; ARTICLE; CAENORHABDITIS ELEGANS; CHEMICAL COMPOSITION; CHEMOTAXIS ASSAY; CHINESE MEDICINE; DRUG SYNTHESIS; GENE EXPRESSION; GINSENG; NONHUMAN; OPHIOPOGON JAPONICUS; PARALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHISANDRA CHINENSIS; ANIMAL; CHEMISTRY; CHEMOTAXIS; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; PANAX; SCHISANDRA; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; CHEMOTAXIS; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; HUMANS; OPHIOPOGON; PANAX; PARALYSIS; PEPTIDE FRAGMENTS; SCHISANDRA;

EID: 84958754805     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-015-0326-z     Document Type: Article

References (53)

1. Abbas S, Wink M (2010) Epigallocatechin gallate inhibits beta amyloid oligomerization in Caenorhabditis elegans and affects the daf-2/insulin-like signaling pathway. Phytomedicine 17:902–909
2. Akiyama H, Barger S, Barnum S (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21:383–421
3. Alzheimer’s Association (2013) Alzheimer’s Association Report: 2013 Alzheimer’s disease facts and figures. Alzheimer’s Dementia 9:208–245
4. Bargmann CI, Hartwieg E, Horvitz HR (1993) Odorant-selective genes and neurons mediate olfaction in C. elegans. Cell 74:515–527
5. Bartus RT, Dean RL, Beer B et al (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–414
6. Bharadwaj PR, Dubey AK, Masters CL et al (2009) Abeta aggregation and possible implications in Alzheimer’s disease pathogenesis. J Cell Mol Med 13:412–421
7. Burns A, Iliffe S (2009) Alzheimer’s disease. BMJ 338:b158
8. Chang Y, Yao H, Chien D, Yeh T (2008) High-performance liquid chromatography-electrospray mass spectrometry for the simultaneous determination of multiple active components in Sheng-Mai San, a prescription of traditional Chinese medicine. Phytochem Anal 19:258–265
9. Che C, Wang Z, Chow MSS et al (2013) Herb–herb combination for therapeutic enhancement and advancement: theory, practice and future perspectives. Molecules 18:5125–5141
10. Chiu PY, Lam PY, Leung HY et al (2011) Co-treatment with Shengmai San-derived herbal product ameliorates chronic ethanol-induced liver damage in rats. Rejuv Res 14:17–23
11. Chui D, Tanahashi H (1999) Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 5:560–564
12. Cooper NR, Kalaria RN (2000) Key issues in Alzheimer’s disease inflammation. Neurobiol Aging 21:451–453
13. Culetto E, Combes D, Fedon Y et al (1999) Structure and promoter activity of the 59 flanking region of ace-1, the gene encoding acetylcholinesterase of class A in Caenorhabditis elegans. J Mol Biol 290:951–966
14. Dasilva KA, Shaw JE, McLaurin JA (2010) Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention. Exp Neurol 223:311–321
15. Diomede L, Cassata G, Fiordaliso F et al (2010) Tetracycline and its analogues protect Caenorhabditis elegans from β amyloid-induced toxicity by targeting oligomers. Neurobiol Dis 40:424–431
16. Dostal V, Link CD (2010) Assaying β-amyloid toxicity using a transgenic C. elegans model. J Vis Exp 44:e2252
17. Dostal V, Roberts CM, Link CD (2010) Genetic mechanisms of coffee extract protection in a Caenorhabditis elegans model of β-amyloid peptide toxicity. Genetics 186:857–866
18. Forloni G, Colombo L, Girola L et al (2010) Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 487:404–407
19. Geula C, Wu CK, Saroff D et al (1998) Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat Med 4:827–831
20. Giridharan VV, Thandavarayan RA, Konishi T (2011) Effect of Shengmai-san on cognitive performance and cerebral oxidative damage in BALB/c Mice. J Med Food 14:601–609
21. Goedert M, Spillantini MG (2006) A century of Alzheimer’s disease. Science 314:777–781
22. Gong M, Wang L, Wang Q et al (2007) Effects of Shengmai San on oxidative damage in mentally stressed mice. Chin J Pathophysiol 23:1216–1218
23. Gutierrez-Zepeda A, Santell R, Wu Z et al (2005) Soy isoflavone glycitein protects against beta amyloid-induced toxicity and oxidative stress in transgenic Caenorhabditis elegans. BMC Neurosci 6:54–62
24. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356
25. Holmes C, Boche D, Wilkinson D, Yadegarfar G et al (2008) Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow—up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223
26. Hsia AY, Masliah E, McConlogue L et al (1999) Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc Natl Acad Sci USA 96:3228–3233
27. Ichikawa H, Konishi T (2002) In vitro antioxidant potentials of traditional Chinese medicine, Shengmai san and their relation to in vivo protective effect on cerebral oxidative damage in rats. Biol Pharmaceut Bull 25:898–903
28. Ichikawa H, Wang X, Konishi T (2003) Role of component herbs in antioxidant activity of Shengmai San-a traditional Chinese medicine formula preventing cerebral oxidative damage in rat. Am J Chinese Med 31:509–521
29. Inestrosa NC, Carvajal FJ, Zolezzi JM et al (2013) Peroxisome proliferators reduce spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenic mice model of Alzheimer’s disease. J Alzheimer’s Dis 33(4):941–959
30. Jiang M, Kang L, Wang Y et al (2014) A metabonomic study of cardioprotection of ginsenosides, schizandrin, and ophiopogonin D against acute myocardial infarction in rats. BMC Complement Altern Med 14:350
31. Leong PK, Chen N, Chiu PY et al (2010) Long-term treatment with Shengmai San-derived herbal supplement (Wei Kang Su) enhances antioxidant response in various tissues of rats with protection against carbon tetrachloride hepatotoxicity. J Med Food 13:427–438
32. Li YJ, Gong M, Konishi T (2007) Antioxidant synergism among component herbs of traditional Chinese medicine formula, Shengmai San studied in vitro and in vivo. J Health Sci 53:692–699
33. Link CD (1995) Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 92:9368–9372
34. Lundberg JM, Änggärd A, Fahrenkrug J et al (1980) Vasoactive intestinal polypeptide in cholinergic neurons of exocrine glands: functional significance of coexisting transmitters for vasodilation and secretion. Proc Natl Acad Sci USA 77:1651–1655
35. Martorell P, Bataller E, Llopis S et al (2013) A cocoa peptide protects Caenorhabditis elegans from oxidative stress and β-Amyloid peptide toxicity. PLoS One 8:e63283
36. Matsuura T, Sato T, Shingai R (2005) Interactions between Caenorhabditis elegans individuals during chemotactic response. Zool Sci 22:1095–1103
37. McGleenon BM, Dynan KB, Passmore AP (1999) Acetylcholinesterase inhibitors in Alzheimer’s disease. Br J Clin Pharmacol 48:471–480
38. Miksys SL, Tyndale RF (2010) Neurodegenerative diseases: a growing challenge. Clin Pharmacol Ther 88:427–430
39. Nishida H, Kushida M, Nakajima Y et al (2007) Amyloid-β-induced cytotoxicity of PC-12 cell was attenuated by Shengmai-san through redox regulation and outgrowth induction. J Pharmacol Sci 104:73–81
40. Prince M, Jackson J (2009) ADI. World Alzheimer report 2009 [M]. London, UK: Alzheimer’s Disease International
41. Ríos JA, Cisternas P, Arrese M et al (2014) Is Alzheimer’s disease related to metabolic syndrome? A Wnt signaling conundrum. Prog Neurobiol 121:125–146
42. Sangha JS, Sun X, Wally OSD et al (2012) Liuwei Dihuang (LWDH), a traditional Chinese medicinal formula, protects against β-amyloid toxicity in transgenic Caenorhabditis elegans. PLoS ONE 7:e43990
43. Schlesinger MJ (1990) Heat shock proteins. J Biol Chem 265:12111–12114
44. Sridhar V, Jaroslaw K, Marina A (2001) Different mechanisms of oxidative stress and neurotoxicity for Alzheimer’s Aβ(1–42) and Aβ(25–35). J Am Chem Soc 123:5625–5631
45. Tabet N (2006) Acetylcholinesterase inhibitors for Alzheimer’s disease: antiinflammatories in acetylcholine clothing! Age Ageing 35:336–338
46. Tan J, Town T, Paris D et al (1999) Microglial activation resulting from CD40-CD40L interaction after β-amyloid stimulation. Science 286:2352–2355
47. Wan F, Zhi D, Liu D et al (2014) Lifespan extension in Caenorhabditis elegans by several traditional Chinese medicine formulas. Biogerontology 15:377–387
48. Wenk GL, Quack G, Moebius HJ et al (2000) No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci 66:1079–1083
49. Wu Y, Wu Z, Butko P et al (2006) Amyloid-β-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26:13102–13113
50. Wu F, Sun H, Wei W et al (2011) Rapid and global detection and characterization of the constituents in ShengMai San by ultra-performance liquid chromatography-high-definition mass spectrometry. J Sep Sci 34:3194–3199
51. Xin L, Yamujala R, Wang Y et al (2013) Acetylcholineestarase-inhibiting alkaloids from Lycoris radiata delay paralysis of amyloid beta-expressing transgenic C. elegans CL4176. PLoS One 8:e63874
52. Xu N, Qiu C, Wang W et al (2011) HPLC/MS/MS for quantification of two types of neurotransmitters in rat brain and application: myocardial ischemia and protection of Sheng-Mai-San. J Pharmaceut Biomed 55:101–108
53. Zhang YS (1978) Medicine Origin; People’s Medical Publishing House: Beijing, China p. 73